Figure 6
Efficacy of JBSNF-000028 in genetic model of type-2 diabetes (db/db mice). (A) Body weight changes (%) and cumulative energy intake in db/– control animals and db/db animals treated with vehicle or JBSNF-000028 at 50 mg kg−1. (B) Fed blood glucose and fed plasma insulin profile of db/– control animals and db/db animals treated with vehicle or JBSNF-000028 at 50 mg kg−1. (C) Plasma total cholesterol, plasma LDL cholesterol, plasma HDL cholesterol, MNA measurements in liver and visceral WAT samples of db/– control animals and db/db animals treated with vehicle or JBSNF-000028 at 50 mg kg−1. (D) OGTT profile, (E) Area under the curve (AUC), (F) plasma glucose and (G) plasma insulin levels at the time of the glucose bolus. (H) Plasma insulin levels at t = 15 min after the glucose bolus in the OGTT. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 when compared with db/– control and $$$$p < 0.0001 when compared with db/db vehicle control. Two way ANOVA followed by Bonferroni’s post-hoc test (A, B, D); One way ANOVA followed by Bonferroni’s post-hoc test (C, E–H).
